Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, or a pharmaceutically acceptable salt thereof, that can be administered to a human subject in need thereof. The disclosure also provides pharmaceutical compositions for treatment of orthostatic hypotension that can be administered once or twice a day.

Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

Abstract: Provided are a superabsorbent polymer and a preparation method thereof. More particularly, provided are a superabsorbent polymer including a fine powder reassembly, wherein the superabsorbent polymer exhibits excellent absorption performances and absorption rate, and does not cause deterioration of physical properties such as water retention capacity (CRC) or absorbency under pressure (AUP), and a preparation method thereof.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: A hydrophilic inorganic powder having excellent self-dispersibility in water or an aqueous solvent, which could not be conventionally achieved, and a cosmetic preparation containing the hydrophilic inorganic powder are provided by combining a hydrophilic surfactant and lipophilic surfactant. There is provided the hydrophilic inorganic powder comprising an inorganic powder as a base material; a hydrophobic-coat that covers the surface of the inorganic powder; and a hydrophilic-coat that covers the hydrophobic-coat, wherein ingredients of the hydrophilic-coat comprises both a hydrophilic surfactant and a lipophilic surfactant, and each of the hydrophilic surfactant and the lipophilic surfactant has a branched alkyl moiety in their molecules, wherein the hydrophilic inorganic powder has self-dispersibility in water or an aqueous solvent.

Abstract: Methods for forming particulates that are highly consistent with regard to shape, size, and content are described. Particulates are suitable for use as reference materials. Methods can incorporate actinides and/or lanthanides, e.g., uranium, and can be used for forming certified reference materials for use in the nuclear industry. Methods include formation of an aerosol from an oxalate salt solution, in-line diagnostics, and collection of particles of the aerosol either in a liquid impinger or on a solid surface.

Abstract: The present invention relates to sensors for detecting the presence or measuring the concentration of a target analyte, the sensor comprising: (i) a first phase comprising a first crosslinked polymer; (ii) a second phase comprising a second crosslinked polymer; and (ill) a target analyte recognition agent; the first phase and second phase arranged to form an optical grating. The first crosslinked polymer comprises low amounts of a crosslinking agent. The present invention also relates to methods of making a sensor for detecting the presence or measuring the concentration of a target analyte.

Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.

Abstract: A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an ? adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating ? adrenergic receptor of the patient with an agonist of the receptor.

Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Abstract: The present disclosure provides feeder hydrogel particles that can function to support the growth, proliferation, and/or activation of a target cell in culture. The present disclosure also provides methods of culturing target cells with feeder hydrogel particles.

Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

Abstract: Masking particles which comprise a drug-containing particle containing a drug, an acid, and a carbonate, the drug-containing particle being coated with a coating layer containing a water-insoluble polymer sufficiently suppress drug release in the oral cavity and pharynx, rapidly release a drug after swallowing, and easily control the release suppression time of a drug. The acid may be at least one organic acid. The carbonate may be at least one water-soluble carbonate. Oral pharmaceutical compositions include tablets, granules, fine granules, powders.

Abstract: There is provided an ocular drug delivery formulation comprising a delivery carrier comprising a cellulosic polymer and an anionic polysaccharide and nanoparticles comprising an amphiphilic non-ionizable block copolymer and a cannabinoid. The formulation has a gel point of about 30° C. to about 37° C.

Abstract: Laundry care additive particles and a dryer sheet that include a water soluble carrier and capsules characterized by substantially inorganic shells, for example silica-based shells. The present disclosure further relates to methods of making and using such compositions.

Abstract: A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl4 and gaseous or vaporous H2O at a reduced temperature and in the absence of a catalyst.

Abstract: The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances.

Abstract: Provided is an antibacterial liquid with excellent temporal stability in which caking due to sedimentation of solid components does not occur and with which a film capable of stably maintaining antibacterial properties can be formed, in a case of being formed into a film. Also provided are an antibacterial film formed using the antibacterial liquid, and a spray and a cloth including the antibacterial liquid. The antibacterial liquid includes an antibacterial microparticle, a binder, and a solvent, in which the antibacterial microparticle contains a silver-supporting inorganic oxide, the binder includes at least one compound having a siloxane bond, the solvent includes an alcohol and water, the concentration of solid contents is less than 5% by mass with respect to the total mass of the antibacterial liquid, and the content of the compound having a siloxane bond is 60% by mass or more with respect to the total solid content of the antibacterial liquid.

Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Abstract: The present disclosure relates to a method for treating or preventing a viral and/or bacterial respiratory infection in a subject, the method comprising administering to the respiratory tract of the subject an effective amount of one or more bacteria from family Pasteurellaceae.

Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.

Abstract: The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.

Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

Abstract: The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.

Abstract: Exemplary embodiments of the present invention relate to a combination formulation for treatment or enhancing the therapy of liver disease, and more particularly, to a combination formulation prepared by containing colchicine and metformin as main active ingredients. The composition according to exemplary embodiments of the present invention may be used as an effective therapeutic agent for liver disease capable of treating and preventing liver fibrosis, liver cirrhosis, liver cancer, or hepatitis by reducing the amount of fat accumulated in the liver tissues by a synergistic effect of colchicine and metformin and lowering glucose tolerance and insulin tolerance and further, may be used as an excellent drug capable of replacing ursodeoxycholic acid.

Abstract: The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration.

Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.

Abstract: The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

Abstract: This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.

Abstract: The disclosure relates to a protein-type nanoparticle for multi-specific antibody delivery, a preparation method, and its application. The protein-type nanoparticle includes a polyester and a protein with a hydrophobic domain, and the hydrophobic domain of the protein is bound with the polyester through hydrophobic interactions. The protein is at least one of albumin, globulin and cell wall protein. The protein-type nanoparticle of the present disclosure has excellent stability and biocompatibility. The protein-type nanoparticle is used to prepare a multi-specific antibody delivery platform (?Fc-NP) by binding anti-IgG-Fc antibody or anti-IgG-Fc antibody fragment, which can stably, quickly and easily bind to multiple specific antibodies through antigen-antibody interaction and enhance the therapeutic effect of specific antibodies.

Abstract: An electroluminescent device includes a first electrode and a second electrode facing each other; an emission layer disposed between the first electrode and the second electrode and including a plurality of quantum dots and a first hole transporting material having a substituted or unsubstituted C4 to C20 alkyl group attached to a backbone structure; a hole transport layer disposed between the emission layer and the first electrode and including a second hole transporting material; and an electron transport layer disposed between the emission layer and the second electrode.

Abstract: A non-aspirating dispenser containing a gel therein for delivery to a desired surface such as a medical article. More specifically, a gel that is dispensed in the form of droplets that are free of air or a gas therein and with reduced drift potential. The dispenser has a container having a flexible bag therein enclosing a thixotropic gel, and has a pressurized gas that is capable of exerting pressure on the bag and forcing the gel out of said bag in a steady stream upon pressing an actuator that is operatively connected to an ejection valve. The bag is free of propellants, and does not produce an aerosol. The gel is thixotropic and is utilized for keeping medical instruments moist in order to prevent soils present thereon from drying out, which can make reprocessing of medical instruments more difficult and less effective. The dispenser implemented at a point of use for transport or prior to delayed reprocessing in the reprocessing area.

Abstract: Polymeric nanoparticles comprising a defined set of biologically active agents that provide for targeted stimulation of non-responsive T cells, e.g. T cells involved in cancer, are provided.

Abstract: Described are compositions and methods relate to stable, high-payload, non-porous enzyme-containing coated granules with improved resistance to activity loss during steam pelleting.

Abstract: An aerogel carrying an active material, and a composite of a hydrogel and the aerogel are provided. The method for preparing the composite according to the present invention comprises the steps of preparing a plurality of aerogel particles having an active material in the pores, preparing a polymer solution in which a polymer is dissolved in a water-soluble solvent, preparing an aerogel/polymer dispersion by homogenizing after mixing the aerogel particles in the polymer solution, and preparing an aerogel/hydrogel composite carrier by mixing the dispersion with a crosslinking agent solution. According to the present invention, by producing a hydrogel composite in which a plurality of aerogel particles is distributed, a complex carrier in which oil and moisture can be carried simultaneously without any surfactant can be provided. Furthermore, a composite carrier having improved properties such as low density, high strength, high component content and stable desorption can be prepared.

Abstract: Liquid fabric care compositions that include certain fabric treatment adjuncts and/or water, where the compositions further include capsules characterized by substantially inorganic shells, for example silica-based shells. The present disclosure further relates to methods of making and using such compositions.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Abstract: The present invention relates to a composite preparation in a core tablet form, composed of an inner core containing rabeprazole as an effective ingredient; an outer layer portion including the bilayer structure of a sustained release layer and an immediate release layer and containing mosapride as an effective ingredient. The core tablet composite preparation according to the present invention is characterized by exerting sufficient pharmacological activity of rabeprazole and mosapride even upon administration of one tablet once a day.

Abstract: The invention relates to polyelectrolyte multilayer coatings and, methods for their preparation and application to substrates to enhance the bioactivity and corrosion protection of the substrates' surface. The invention is particularly suitable for coating substrates employed for medical applications, such as but not limited to medical implant devices for drug and/or biologics delivery in a patient. The substrate has a positive or negative charge. The polyelectrolyte multilayer coatings include at least a first polymer layer and a second polymer layer. The first polymer and second polymer have opposite charges. Each of the polymer layers is individually applied using a layer-by-layer such that an alternating charge multilayer coating is formed.

Abstract: Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms of Compound I dihydrochloride.

Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.